Any current/future new fundraising through debt or equity?

The transcript provided on pages 4-16 of the document does not explicitly mention any current or planned new fundraising through debt or equity. The balance sheet remains healthy with a net debt to EBITDA ratio of 0.45x as of Q3 FY24, indicating manageable leverage. There is no mention of raising new capital through equity or additional debt in the near term. The company is focusing on operational improvements, bed expansions, and divestments but no active fundraising exercises are disclosed. Private equity investors in Agilus have an exit timeline around April 2024, connected to a potential I

Any current/future capex/capital investment/strategic investment?

The company has already spent INR 450 crores in capex during the current 9 months, with similar trends expected in the coming quarter. Investments include state-of-the-art technology such as Gamma Knife, MR-Linac, two Linac replacements, a Da Vinci robotic surgery system, and an orthopedic robot (~INR 5-6 crores). The focus is on expanding high-end specialties like oncology, neurology, and robotic surgeries to drive ARPOB increases and margin improvements. Brownfield bed expansions are planned to add nearly 2,200 beds over the next 4 years, with ~350 beds from an acquired hospital (Medeor, Man

Future growth expectations in sales/revenue/volumes?

Fortis Healthcare plans to add approximately 2,200 beds over the next 4 years, focusing primarily on brownfield expansions within existing hospitals to leverage operational efficiencies. New facility openings include a 70-bed unit in Ludhiana and bed additions in Mulund, Kolkata, Bangalore, and Manesar, supporting volume growth. Revenue growth is expected from increased occupancy (currently around 64-67%, with a target to reach ~70% and beyond), and a rising contribution from high-end specialties like oncology, neurosciences, and robotic surgeries. ARPOB (Average Revenue per Occupied Bed) grow

Future growth expectations in earnings/operating earnings/profits/EPS?

Earnings momentum remains healthy, particularly in the hospital business, with well-defined growth levers such as brownfield expansions, advanced medical programs, and superior patient experience. Bed expansion plan includes ~2,200 beds over the next 4 years, primarily through brownfield expansions in existing facilities, aiding margin improvement. EBITDA margin targets: aiming for ~20% margin by year-end; long-term goal to achieve ~25% EBITDA margin over 3-4 years with ramp-up in occupancy and bed utilization. ARPOB (Average Revenue Per Occupied Bed) growth expected around 5% going forward, d

IN US

Sale is live|00:00:00left today

Fortis Healthcare LtdQ4 FY25Healthcare Services

Fortis Healthcare Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹971P/E: 72.2Market Cap: ₹72.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Fortis Healthcare plans to add approximately 2,200 beds over the next 4 years, focusing primarily on brownfield expansions within existing hospitals to leverage operational efficiencies.
→New facility openings include a 70-bed unit in Ludhiana and bed additions in Mulund, Kolkata, Bangalore, and Manesar, supporting volume growth.
→Revenue growth is expected from increased occupancy (currently around 64-67%, with a target to reach ~70% and beyond), and a rising contribution from high-end specialties like oncology, neurosciences, and robotic surgeries.
→ARPOB (Average Revenue per Occupied Bed) growth will moderate from previous high levels (~19%) to a sustainable ~5% driven by a growing mix of complex, high-value procedures.
→International patient revenue is stabilizing after recent geopolitical impacts and is expected to return to prior levels.
→Digital channel revenues grew 32% YoY, indicating growth in digital engagement and revenues from online sources.

Margin guidance

Category 3

→Earnings momentum remains healthy, particularly in the hospital business, with well-defined growth levers such as brownfield expansions, advanced medical programs, and superior patient experience.
→Bed expansion plan includes ~2,200 beds over the next 4 years, primarily through brownfield expansions in existing facilities, aiding margin improvement.
→EBITDA margin targets: aiming for ~20% margin by year-end; long-term goal to achieve ~25% EBITDA margin over 3-4 years with ramp-up in occupancy and bed utilization.
→ARPOB (Average Revenue Per Occupied Bed) growth expected around 5% going forward, driven by high-end specialty cases.
→Operational efficiencies and cost optimization efforts are expected to support profitability.
→Divestments (e.g., Malar hospital) contribute modestly (~0.5-0.6% margin improvement).
→Occupancy anticipated to improve to ~70% in upcoming quarters, supporting margin expansion.
→Gradual improvement expected in lower-margin hospitals over 2-3 years.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript provided on pages 4-16 of the document does not explicitly mention any current or planned new fundraising through debt or equity.
→The balance sheet remains healthy with a net debt to EBITDA ratio of 0.45x as of Q3 FY24, indicating manageable leverage.
→There is no mention of raising new capital through equity or additional debt in the near term.
→The company is focusing on operational improvements, bed expansions, and divestments but no active fundraising exercises are disclosed.
→Private equity investors in Agilus have an exit timeline around April 2024, connected to a potential IPO, but no direct new equity issuance by the company is detailed.
→Overall, no explicit plans or announcements of fresh fundraising through debt or equity are described in the current transcript.

Order book

The provided transcript from Fortis Healthcare's Investors/Analysts Meet on February 8, 2024, does not explicitly mention details about the current or expected order book or pending orders. The discussion primarily focuses on: - Bed capacity expansion plans, including addition of ~2,200 beds with significant brownfield expansions. - Expectation of margin improvement over the next 3-4 years. - Operational updates on hospitals like Faridabad, Ludhiana, and Manesar acquisitions. - Divestment strategy with no immediate active plans apart from a very small hospital. - Capital expenditure of INR 450 crores already spent in 9 months on medical technology upgrades. No references to specific orderbooks or pending orders related to sales or contracts were mentioned in the transcript.

Capex plans

Yes

→The company has already spent INR 450 crores in capex during the current 9 months, with similar trends expected in the coming quarter.
→Investments include state-of-the-art technology such as Gamma Knife, MR-Linac, two Linac replacements, a Da Vinci robotic surgery system, and an orthopedic robot (~INR 5-6 crores).
→The focus is on expanding high-end specialties like oncology, neurology, and robotic surgeries to drive ARPOB increases and margin improvements.
→Brownfield bed expansions are planned to add nearly 2,200 beds over the next 4 years, with ~350 beds from an acquired hospital (Medeor, Manesar) and other expansions across existing facilities.
→New facilities and expansions (e.g., Ludhiana, Manesar, Noida) will be operationalized based on occupancy ramp-up to ensure cost-effective bed addition.
→Strategic moves include portfolio rationalization by divesting loss-making facilities to improve overall profitability.
→The company maintains margin guidance aiming for 25% EBITDA margin over 3-4 years with these investments.

How does Fortis Healthcare Ltd rank vs peers in Healthcare Services?

Pro feature

1Fortis Healthcare Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Fortis Healthcare Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio